MA56098A - Immunomodulateurs hétérocycliques utilisés comme inhibiteur de point de contrôle pdl1 - Google Patents
Immunomodulateurs hétérocycliques utilisés comme inhibiteur de point de contrôle pdl1Info
- Publication number
- MA56098A MA56098A MA056098A MA56098A MA56098A MA 56098 A MA56098 A MA 56098A MA 056098 A MA056098 A MA 056098A MA 56098 A MA56098 A MA 56098A MA 56098 A MA56098 A MA 56098A
- Authority
- MA
- Morocco
- Prior art keywords
- heterocyclic
- checkpoint inhibitor
- immunomodulators used
- pdl1
- pdl1 checkpoint
- Prior art date
Links
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 title 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 title 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title 1
- 239000002955 immunomodulating agent Substances 0.000 title 1
- 229940121354 immunomodulator Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19179072 | 2019-06-07 | ||
| PCT/EP2020/065646 WO2020245372A1 (fr) | 2019-06-07 | 2020-06-05 | Immunomodulateurs hétérocycliques utilisés comme inhibiteur de point de contrôle pdl1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA56098A true MA56098A (fr) | 2022-04-13 |
| MA56098B1 MA56098B1 (fr) | 2023-10-31 |
Family
ID=66793871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA56098A MA56098B1 (fr) | 2019-06-07 | 2020-06-05 | Immunomodulateurs hétérocycliques autant qu'inhibiteurs de pdl1 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220259186A1 (fr) |
| EP (1) | EP3980413B1 (fr) |
| JP (1) | JP2022535879A (fr) |
| KR (1) | KR20220017942A (fr) |
| CN (1) | CN113966329B (fr) |
| AU (1) | AU2020286962A1 (fr) |
| BR (1) | BR112021023780A2 (fr) |
| CA (1) | CA3138494A1 (fr) |
| ES (1) | ES2956866T3 (fr) |
| HR (1) | HRP20230873T1 (fr) |
| HU (1) | HUE063236T2 (fr) |
| MA (1) | MA56098B1 (fr) |
| MD (1) | MD3980413T2 (fr) |
| MX (1) | MX2021015048A (fr) |
| PL (1) | PL3980413T3 (fr) |
| RS (1) | RS64681B1 (fr) |
| WO (1) | WO2020245372A1 (fr) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016004194A8 (pt) * | 2013-09-04 | 2020-02-11 | Bristol Myers Squibb Co | compostos úteis como imunomoduladores |
| US9850225B2 (en) * | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| KR20190133714A (ko) * | 2017-03-27 | 2019-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제로서 유용한 치환된 이소퀴놀린 유도체 |
-
2020
- 2020-06-05 MD MDE20220403T patent/MD3980413T2/ro unknown
- 2020-06-05 BR BR112021023780A patent/BR112021023780A2/pt unknown
- 2020-06-05 CN CN202080041699.XA patent/CN113966329B/zh active Active
- 2020-06-05 WO PCT/EP2020/065646 patent/WO2020245372A1/fr active Application Filing
- 2020-06-05 KR KR1020217042602A patent/KR20220017942A/ko unknown
- 2020-06-05 EP EP20730279.5A patent/EP3980413B1/fr active Active
- 2020-06-05 US US17/595,711 patent/US20220259186A1/en active Pending
- 2020-06-05 HU HUE20730279A patent/HUE063236T2/hu unknown
- 2020-06-05 MX MX2021015048A patent/MX2021015048A/es unknown
- 2020-06-05 RS RS20230805A patent/RS64681B1/sr unknown
- 2020-06-05 CA CA3138494A patent/CA3138494A1/fr active Pending
- 2020-06-05 HR HRP20230873TT patent/HRP20230873T1/hr unknown
- 2020-06-05 ES ES20730279T patent/ES2956866T3/es active Active
- 2020-06-05 JP JP2021572339A patent/JP2022535879A/ja active Pending
- 2020-06-05 AU AU2020286962A patent/AU2020286962A1/en active Pending
- 2020-06-05 MA MA56098A patent/MA56098B1/fr unknown
- 2020-06-05 PL PL20730279.5T patent/PL3980413T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022535879A (ja) | 2022-08-10 |
| PL3980413T3 (pl) | 2023-12-27 |
| CN113966329A (zh) | 2022-01-21 |
| WO2020245372A1 (fr) | 2020-12-10 |
| MD3980413T2 (ro) | 2023-12-31 |
| MX2021015048A (es) | 2022-01-18 |
| EP3980413C0 (fr) | 2023-07-19 |
| BR112021023780A2 (pt) | 2022-01-11 |
| CA3138494A1 (fr) | 2020-12-10 |
| CN113966329B (zh) | 2024-08-13 |
| EP3980413A1 (fr) | 2022-04-13 |
| MA56098B1 (fr) | 2023-10-31 |
| ES2956866T3 (es) | 2023-12-29 |
| KR20220017942A (ko) | 2022-02-14 |
| US20220259186A1 (en) | 2022-08-18 |
| HUE063236T2 (hu) | 2024-01-28 |
| EP3980413B1 (fr) | 2023-07-19 |
| AU2020286962A1 (en) | 2022-02-03 |
| RS64681B1 (sr) | 2023-11-30 |
| HRP20230873T1 (hr) | 2024-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3873903T3 (da) | Substituerede 6-azabenzimidazolforbindelser som hpk1-hæmmere | |
| MA46045A (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| MA45669A (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| MA55633A (fr) | Salicylamides de spiroheptane et composés associés utilisés comme inhibiteurs de rock | |
| DK3684767T3 (da) | Heterocykliske forbindelser som pad-inhibitorer | |
| MA44860A (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| CL2021001078A1 (es) | 2-amino-n-heteroarilo-nicotinamidas como inhibidores de nav1.8. | |
| DK3788040T3 (da) | Pyridazinoner som parp7-inhibitorer | |
| MA52413A (fr) | Inhibiteurs de cd73 | |
| JP1679815S (ja) | エアロゾル発生器用充電器 | |
| DK3768674T3 (da) | Aminopyrimidinderivater som ctps1-hæmmere | |
| TWI799692B (zh) | 靜電吸盤 | |
| MA46203A (fr) | Utilisations d'un inhibiteur d'homologue 2 de lysyl-oxydase | |
| MA55909A (fr) | Inhibiteurs de cdk | |
| MA47420A (fr) | Composés inhibiteurs d'oga | |
| DE102020112518B8 (de) | Toner | |
| DK3861001T3 (da) | Bor, som indeholder PDE4-hæmmere | |
| DK3749646T3 (da) | Heteroaryl-forbindelser som kinase-inhibitor | |
| DK3833665T3 (da) | Diazabicyclooctanoner som hæmmere af serin-beta-lactamaser | |
| MA51611A (fr) | Inhibiteurs de pi4kiiibêta | |
| CO2022001860A2 (es) | Derivados quinolina como inhibidores de proteína quinasa | |
| DK3891142T3 (da) | Heteroaromatiske forbindelser som vanininhibitorer | |
| MA56098A (fr) | Immunomodulateurs hétérocycliques utilisés comme inhibiteur de point de contrôle pdl1 | |
| MA55074A (fr) | Dérivés de pyrazolopyridine utilisés comme inhibiteurs de pask | |
| EP3802530C0 (fr) | Composés hétérocycliques comme inhibiteurs de phosphoinositide 3-kinase de classe ii |